Royalty Pharma to Announce Third-Quarter 2021 Financial Results on November 10, 2021

Rhea-AI Summary

Royalty Pharma (RPRX) will release its Q3 2021 financial results on November 10, 2021, before U.S. markets open. The announcement includes a conference call at 8:00 a.m. ET, accessible via phone and webcast. Royalty Pharma, a leader in biopharmaceutical royalties, partners with innovators to fund clinical trials and acquire royalties from top therapies, including Imbruvica and Xtandi. The company has royalties on over 45 commercial products and nine developmental candidates, positioning it as a significant player in the biopharmaceutical sector.

Positive

• Royalty Pharma's portfolio includes royalties on over 45 commercial products, indicating a strong revenue base.
• The company is recognized as a leading funder of innovation in the biopharmaceutical industry.

Negative

• None.

NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

The conference call can be accessed live over the phone for U.S. callers by dialing (833) 519-1253 or for international callers by dialing +1 (914) 800-3826. The passcode to access the conference call is 1764468.

A live webcast may be accessed from the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small- and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

When will Royalty Pharma report its Q3 2021 financial results?

Royalty Pharma will report its Q3 2021 financial results on November 10, 2021, before U.S. markets open.

What time is the Royalty Pharma conference call for Q3 2021 results?

The conference call for Royalty Pharma's Q3 2021 results is scheduled for 8:00 a.m. Eastern Time on November 10, 2021.

How can I access the Royalty Pharma Q3 2021 results conference call?

You can access the conference call by dialing (833) 519-1253 for U.S. callers or +1 (914) 800-3826 for international callers, with the passcode 1764468.

What is Royalty Pharma's business model?

Royalty Pharma acquires biopharmaceutical royalties and funds innovation by partnering with companies on late-stage clinical trials and new product launches.

What products does Royalty Pharma have royalties on?

Royalty Pharma's portfolio includes royalties on major therapies such as AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ Xtandi, and Gilead’s Trodelvy.